FDA critics: Agency needs to overhaul safety processes

The controversy surrounding GlaxoSmithKline's (NYSE: GSK) diabetes drug Avandia points to a need for changes in the way the FDA handles safety issues, agency critics told U.S. lawmakers during a House subcommitee hearing. Report